Desmopressin

Evidence Level: L5

Predicted Indications: 6

Desmopressin

Pharmacist Assessment Report

Desmopressin: synthetic vasopressin analogue (V2 receptor agonist) → congenital prothrombin deficiency (congenital prothrombin deficiency)

One-Sentence Summary

Desmopressin is a synthetic analogue of vasopressin that is marketed in Canada in several injectable, nasal and oral products. The TxGNN model predicts it may be effective for congenital prothrombin deficiency, but there are no clinical trials and only 1 publication (a 1993 general review of inherited bleeding disorders), so the evidence is very weak.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	congenital prothrombin deficiency
TxGNN Prediction Score	0.9970
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 10 of 10)
Number of DINs	10 (marketed: 10)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not currently available in the data compiled for this report. Based on general pharmacology, desmopressin acts on the V2 receptor and triggers release of von Willebrand factor (vWF) and factor VIII from endothelial stores.

Prothrombin (factor II) is not part of this pathway. Desmopressin does not raise prothrombin levels, so there is no clear mechanistic rationale for this prediction. The single article linked to it is a 1993 general review of congenital bleeding disorders, not a study of prothrombin deficiency. The high score most likely reflects the closeness of coagulation disorders in the model’s training data rather than a true therapeutic link. No study directly addresses this disease, so the evidence level is L5.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
7684674	1993	Review	Drugs	General overview of treatment options for inherited bleeding disorders such as haemophilia A and von Willebrand disease; does not study prothrombin deficiency or show a benefit of desmopressin for it

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02513579	BIPAZEN	Not recorded	Not recorded
00873993	DDAVP INJ 4MCG/ML	Not recorded	Not recorded
02284030	APO-DESMOPRESSIN	Not recorded	Not recorded
02024179	OCTOSTIM LIQ INJ. 15MCG/ML	Not recorded	Not recorded
02242465	DESMOPRESSIN SPRAY	Not recorded	Not recorded

Safety Considerations

Drug Interactions: 100 interactions were found in the interaction screen. Examples include:
- Major: hydrocortisone, triamcinolone, dexamethasone, beclomethasone dipropionate, betamethasone, budesonide, prednisolone, prednisone
- Moderate: epinephrine, loperamide, morphine (including liposomal), opium, chlorpropamide
- Minor: acetylsalicylic acid

Other safety details are not available here. Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: Desmopressin works through vWF and factor VIII release and has no known effect on prothrombin. There is no clinical trial and no study that directly addresses congenital prothrombin deficiency, so the score of 0.9970 is not backed by evidence.

To proceed, the following is needed:

A mechanistic rationale showing how desmopressin could affect prothrombin levels or function
Direct clinical or preclinical studies in congenital prothrombin deficiency
Mechanism-of-action data and package insert warnings and contraindications from Health Canada
A review of the interaction profile, especially with corticosteroids, before any further evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.